Kuros Biosciences AG

BATS-CHIXE:KURNz Stock Report

Market Cap: CHF 759.0m

Kuros Biosciences Past Earnings Performance

Past criteria checks 0/6

Kuros Biosciences's earnings have been declining at an average annual rate of -4.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 52.7% per year.

Key information

-4.3%

Earnings growth rate

18.9%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate52.7%
Return on equity-14.8%
Net Margin-16.9%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Kuros Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BATS-CHIXE:KURNz Revenue, expenses and earnings (CHF Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2453-9447
31 Mar 2443-11386
31 Dec 2334-14326
30 Sep 2327-15288
30 Jun 2320-16247
31 Mar 2319-15226
31 Dec 2218-15195
30 Sep 2217-13184
30 Jun 2215-11162
31 Mar 2214-9154
31 Dec 2114-8145
30 Sep 2113-7135
30 Jun 2112-6114
31 Mar 218-9114
31 Dec 204-12104
30 Sep 203-1294
30 Jun 203-1293
31 Mar 203-1284
31 Dec 193-1175
30 Sep 192-1176
30 Jun 191-1287
31 Mar 191-1287
31 Dec 181-1297
30 Sep 180-13114
30 Jun 180-15131
31 Mar 180-16140
31 Dec 171-16150
30 Sep 171-15141
30 Jun 171-13132
31 Mar 171-17151
31 Dec 161-20170
30 Sep 161-19150
30 Jun 161-18140
31 Mar 161-1290
31 Dec 150-640

Quality Earnings: KURNz is currently unprofitable.

Growing Profit Margin: KURNz is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: KURNz is unprofitable, and losses have increased over the past 5 years at a rate of 4.3% per year.

Accelerating Growth: Unable to compare KURNz's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KURNz is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: KURNz has a negative Return on Equity (-14.77%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 10:35
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kuros Biosciences AG is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Laura Pfeifer-RossiBank am Bellevue
Olav ZilianMirabaud Securities Limited
Dylan van HaaftenNIBC Bank N.V.